As of 2024-12-14, the Intrinsic Value of Harvard Bioscience Inc (HBIO) is
2.74 USD. This HBIO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 2.16 USD, the upside of Harvard Bioscience Inc is
26.80%.
The range of the Intrinsic Value is 1.80 - 4.96 USD
HBIO Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
1.80 - 4.96 |
2.74 |
26.8% |
| DCF (Growth 10y) |
2.41 - 5.92 |
3.46 |
60.2% |
| DCF (EBITDA 5y) |
3.56 - 4.01 |
3.77 |
74.6% |
| DCF (EBITDA 10y) |
3.85 - 4.72 |
4.26 |
97.2% |
| Fair Value |
-1.63 - -1.63 |
-1.63 |
-175.57% |
| P/E |
(10.19) - (10.90) |
(10.76) |
-598.0% |
| EV/EBITDA |
1.88 - 2.17 |
2.07 |
-4.2% |
| EPV |
1.77 - 2.45 |
2.11 |
-2.5% |
| DDM - Stable |
(2.57) - (7.52) |
(5.04) |
-333.4% |
| DDM - Multi |
0.89 - 2.06 |
1.25 |
-42.2% |
HBIO Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
94.22 |
| Beta |
1.42 |
| Outstanding shares (mil) |
43.62 |
| Enterprise Value (mil) |
127.51 |
| Market risk premium |
4.60% |
| Cost of Equity |
10.40% |
| Cost of Debt |
6.66% |
| WACC |
9.08% |